Last reviewed · How we verify
brompheniramine + phenylephrine
Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while phenylephrine acts as an alpha-1 adrenergic agonist to constrict blood vessels and reduce nasal congestion.
Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while phenylephrine acts as an alpha-1 adrenergic agonist to constrict blood vessels and reduce nasal congestion. Used for Allergic rhinitis with nasal congestion, Urticaria and pruritus associated with allergic reactions, Upper respiratory allergy symptoms.
At a glance
| Generic name | brompheniramine + phenylephrine |
|---|---|
| Also known as | Group 1 |
| Sponsor | Ache Laboratorios Farmaceuticos S.A. |
| Drug class | Antihistamine + decongestant combination |
| Target | H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Brompheniramine is a first-generation antihistamine that crosses the blood-brain barrier and competitively antagonizes H1 receptors, reducing histamine-mediated allergic responses including itching, sneezing, and urticaria. Phenylephrine is a selective alpha-1 adrenergic agonist that causes vasoconstriction of nasal blood vessels, reducing mucosal edema and nasal congestion. Together, they provide symptomatic relief of allergic rhinitis and upper respiratory congestion.
Approved indications
- Allergic rhinitis with nasal congestion
- Urticaria and pruritus associated with allergic reactions
- Upper respiratory allergy symptoms
Common side effects
- Drowsiness/sedation
- Dry mouth
- Nervousness/excitability
- Headache
- Tachycardia
- Dizziness
Key clinical trials
- Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (PHASE3)
- Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |